category,datetime,headline,id,image,related,source,summary,url
company,1769191913,"Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 25",138229764,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,SYK,SeekingAlpha,"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.",https://finnhub.io/api/news?id=51cad26e98a55cff634e728377ee94ee04cf1e5384eb442f6922079bdc07e397
company,1769186160,Stryker Corp. stock underperforms Friday when compared to competitors,138235680,,SYK,MarketWatch,Stryker Corp. stock underperforms Friday when compared to competitors,https://finnhub.io/api/news?id=d9fb78c75f911bfcd9ec2cb8c8a1f93508e681aacc15e45e3699bb2f1522f8b0
company,1769136778,Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific’s (BSX) Mew Market Dominance,138220893,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,SYK,Yahoo,"Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now. On January 16, Oppenheimer lowered its price target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific’s $14.5 billion acquisition of Penumbra. Although the deal creates a […]",https://finnhub.io/api/news?id=797b355c88d860e8fab0e814e4ed7a3c278b53653f3e5d313b4ebef4292040ab
